Formulation having mobilising activity
The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.
1. A formulation comprising a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and defibrotide as described in Chemical Abstract Registry No. 83712-60-1, wherein said formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.
2. The formulation according to claim 1 , characterized in that the haematopoietic factor having the capacity to mobilize haematopoietic progenitors is G-CSF.
3. The formulation according to claim 1 , characterized in that it is an aqueous solution.
4. The formulation according to claim 1 further comprising an excipient or a coadjuvant.
5. The formulation of claim 1 , wherein defibrotide is in the form of a salt of an alkali metal.
6. The formulation of claim 1 , wherein said alkali metal is sodium.
7. A formulation comprising defibrotide as characterized by Chemical Abstract Registry No. 83712-60-1 and at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, as a combined preparation,
wherein said formulation is effective to increase the number of haematopoietic progenitor cells relative to the increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.
8. The formulation of claim 7 , wherein defibrotide is in the form of a salt of an alkali metal.
9. The formulation of claim 7 , wherein said alkali metal is sodium.
10. The formulation of claim 7 , wherein the haematopoietic factor having the capacity to mobilize haematopoietic progenitors is G-CSF.
11. A method of increasing the amount of stem cells and/or haematopoietic progenitors in the peripheral blood of a mammal comprising administering to the mammal the formulation according to claim 1 ;
wherein administration of said formulation results in an increase in the number of haematopoietic progenitor cells that is greater than the increase in the number of haematopoietic progenitor cells achieved by administration of the haematopoietic factor alone.